<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16474">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02892422</url>
  </required_header>
  <id_info>
    <org_study_id>16159B</org_study_id>
    <secondary_id>2015-003284-11</secondary_id>
    <nct_id>NCT02892422</nct_id>
  </id_info>
  <brief_title>Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia</brief_title>
  <acronym>Debut</acronym>
  <official_title>Interventional, Open-label, Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of the long-term treatment with Lu AF35700.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety study in patients with schizophrenia who have participated and completed a study
      investigating Lu AF35700 including Studies 16159A and 16323A. Or in patients with
      schizophrenia for whom a switch of antipsychotic treatment can be potentially beneficial
      according to the investigator's clinical judgement.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2016</start_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>From dosing to end of study (57 weeks)</time_frame>
    <description>Based on the safety assessments (e.g. clinical safety laboratory tests, vital signs, weight, waist circumference and ECG)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Flexible-dose of Lu AF35700</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF35700</intervention_name>
    <description>Flexible-dose of Lu AF35700, 10 or 20 mg/day, tablets, orally.
From Day 8, the daily dose can be increased to 20mg. Thereafter, the daily dose can be adjusted (decreased to 10mg or following a decrease, increased to 20mg/day)
Patients who completed the 16159A study, only, can be switched to a weekly 70 mg Lu AF35700 dosing regimen (tablets, orally, once weekly) after 8 weeks in this study</description>
    <arm_group_label>Flexible-dose of Lu AF35700</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - For 16159A-patients

          -  The patient has completed Study 16159A.

          -  The patient is able to read and understand the Informed Consent Form.

          -  The patient has signed the Informed Consent Form specific for Study 16159B.

          -  The patient can potentially benefit from 52-week treatment with Lu AF35700 according
             to the investigator's clinical judgement.

        For 16323A-patients

          -  The patient has completed the dosing period of Study 16323A.

          -  The patient is able to read and understand the Informed Consent Form.

          -  The patient has signed the Informed Consent Form specific Study 16159B.

          -  The patient has a confirmed diagnosis of schizophrenia according to DSM-5™.

          -  The patient can potentially benefit from 52-week treatment with Lu AF35700 according
             to the investigator's clinical judgement.

        For Other Patients

          -  The patient has schizophrenia, diagnosed according to DSM-5™.

          -  The patient is a man or woman, aged ≥18 years.

          -  The patient has been prescribed oral antipsychotic treatment at the recommended dose
             range as stated in the summary of product characteristics or equivalent label for 6
             weeks prior to the Screening Visit.

          -  The patient has a PANSS total score ≥60 and ≤90 at Screening and Baseline Visits.

          -  The patient has a Clinical Global Impression - Severity of Illness (CGI-S) score ≤4.

          -  The patient is in need of a change in the current antipsychotic treatment and,
             according to the investigator's clinical judgement, the patient can potentially
             benefit from a switch to another treatment including, but not limited to, any of the
             following reasons:

               -  lack of adequate response to his or her current antipsychotic medication;

               -  poor tolerability to his or her current antipsychotic medication;

               -  unwillingness of the patient to adhere to his or her current antipsychotic
                  medication.

        Exclusion Criteria:

        - For 16159A-patients

          -  The patient has been diagnosed with a primary psychiatric disorder other than
             schizophrenia during Study 16159A.

          -  The patient, in the opinion of the investigator, is at significant risk of suicide,
             or: Answers &quot;Yes&quot; to any question on the Suicidal Behaviour section of the
             Columbia-Suicide Severity Rating Scale (C-SSRS), OR Answers &quot;Yes&quot; to questions 4 and
             5 on the Suicidal Ideation section of the C-SSRS

        For 16323A-patients

          -  The patient has been diagnosed with a primary psychiatric disorder other than
             schizophrenia during Study 16323A.

          -  The patient, in the opinion of the investigator, is at significant risk of suicide,
             or: Answers &quot;Yes&quot; to any question on the Suicidal Behaviour section of the C-SSRS, OR
             Answers &quot;Yes&quot; to questions 4 and 5 on the Suicidal Ideation section of the C-SSRS

        For Other Patients

          -  The patient has any current psychiatric disorder (DSM-5™ criteria) other than
             schizophrenia established as the primary diagnosis.

          -  The patient is experiencing acute exacerbation of psychotic symptoms at the Screening
             Visit, between the Screening and Baseline Visits or at the Baseline Visit.

          -  The patient is treated with clozapine at the time of the Screening Visit.

          -  The patient has a substance use disorder (except nicotine) which according to the
             investigator's judgment may compromise the patient's ability to comply with the study
             procedures, or preclude the benefits of the study medication.

          -  The patient, in the opinion of the investigator, is at significant risk of suicide,
             or: Answers &quot;Yes&quot; to any question on the Suicidal Behaviour section of the C-SSRS, OR
             Answers &quot;Yes&quot; to questions 4 and 5 on the Suicidal Ideation section of the C-SSRS

        Other protocol defined inclusion and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US1399</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1104</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1114</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1392</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1009</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1046</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1171</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1065</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EE1007</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL1043</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL1058</name>
      <address>
        <city>Pruszcz Gdanski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES1047</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 13, 2017</lastchanged_date>
  <firstreceived_date>August 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
